Recital 13, Commission Regulation (EU) No 536/2013 of 11 June 2013 amending Regulation (EU) No 432/2…

In forcesince 11 Jun 2013

Authorisation may also legitimately be withheld if health claims do not comply with other general and specific requirements of Regulation (EC) No 1924/2006, even in the case of a favourable scientific assessment by the Authority. The Authority concluded that for one claim on the effect of L-arginine [Corresponding to entry ID 4683 in the consolidated list.] on the maintenance of normal ammonia clearance and for another claim on the effect of L-tyrosine [Corresponding to entry ID 1928 in the consolidated list.] on the normal synthesis of catecholamines a cause and effect relationship has been established. The Commission and the Member States have considered whether health claims reflecting those conclusions should be authorised. On the basis of the data submitted and of the current scientific knowledge, the Authority concluded that no conditions of use can be defined which would accompany the health claim on L-arginine [http://www.efsa.europa.eu/en/efsajournal/doc/2051.pdf], while for the health claim on L-tyrosine, the Authority proposed as appropriate conditions of use that ‘a food should be at least a source of protein as per Annex to Regulation (EC) No 1924/2006’ [http://www.efsa.europa.eu/en/efsajournal/doc/2270.pdf]. In the Authority’s response of 9 November 2012 to the request of the Commission for clarification, the Authority noted that its conclusions for those claims were based on the known biochemical role of the two amino acids, as contained in protein. It added that it could not provide a quantitative indication of the necessary daily intake of L-tyrosine and L-arginine per se to produce the respective beneficial physiological effects. Accordingly, it is not possible to establish specific conditions for the use of those claims to ensure that the amino acids are contained in the final product in a quantity that will produce the respective beneficial physiological effects in accordance with point (i) of Article 5(1)(b) of Regulation (EC) No 1924/2006. In the absence of such specific conditions of use the beneficial effect of the substance to which the claim relates cannot be assured. Therefore, those claims could be misleading the consumer and should not be included in the lists of permitted health claims.